Appraisal of patient-reported outcome measures in analogous diseases and recommendations for use in phase II and III clinical trials of pyruvate kinase deficiency.Published in:2019By:Salek, M. S.;Ionova, T.;Johns, J. R.;Oliva, E. N.Publication type:journal article
Twice-Weekly High-Dose rHuEpo for the Treatment of Anemia in Patients with Low-Risk Myelodysplastic Syndromes.Published in:Acta Haematologica, 2008, v. 120, n. 2, p. 104, doi. 10.1159/000166864By:Latagliata, R.;Oliva, E. N.;Volpicelli, P.;Carmosino, I.;Breccia, M.;Vincelli, I.;Alati, C.;Napoleone, L.;Vozella, F.;Nobile, F.;Alimena, G.Publication type:Article